A Phase 1, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ART101 in Healthy Participants and Adult Participants With Hypertension
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs ART 101 Arnatar Therapeutics (Primary)
- Indications Hypertension
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Arnatar Therapeutics
- 24 Jan 2025 New trial record